References
- Chhabra SK, Chhabra P. Gender differences in perception of dyspnea, assessment of control and quality of life in asthma. J Asthma 2011;48:609–615
- Lux R, Awa W, Walter U. An interdisciplinary analysis of sex and gender in relation to the pathogenesis of bronchial asthma. Respir Med 2009;103:637–649
- Choi IS. Gender-specific asthma treatment. Allergy Asthma Immunol Res 2011;3:74–80
- Foster JM, Van Sonderen E, Lee AJ, Sanderman R, Dijkstra A, Postma DS, Van der Molen T. A self-rating scale for patient-perceived side effects of ICS. Respir Res 2006;7:131
- Galvan CA, Guarderas JC. Practical considerations for dysphonia caused by ICS. Mayo Clin Proc 2012;87:901–904
- Saruwatari J, Matsunaga M, Ikeda K, Nakao M, Oniki K, Seo T, Mihara S, et al. Impact of CYP2D6*10 on H1-antihistamine-induced hypersomnia. Eur J Clin Pharmacol 2006;62:995–1001
- Temprano J, Mannino DM. The effect of sex on asthma control from the National Asthma Survey. J Allergy Clin Immunol 2009;123:854–860
- Williamson IJ, Matusiewicz SP, Brown PH, Greening AP, Crompton GK. Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations. Eur Respir J 1995;8:590–592
- Lipworth BJ. Clinical pharmacology of corticosteroids in bronchial asthma. Pharmacol Ther 1993;58:173–209
- Rachelefsky GS, Liao Y, Faruqi R. Impact of inhaled corticosteroid-induced oropharyngeal adverse events: results from a meta-analysis. Ann Allergy Asthma Immunol 2007;98:225–238
- Brown PH, Blundell G, Greening AP, Crompton GK. Do large volume spacer devices reduce the systemic effects of high dose ICS? Thorax 1990;45:736–739
- Konig P. Spacer devices used with metered-dose inhalers. Breakthrough or gimmick? Chest 1985;88:276–284
- Van Boven JF, De Jong-van den Berg LT, Vegter S. ICS and the occurrence of oral candidiasis: a prescription sequence symmetry analysis. Drug Saf 2013;36:231–236
- Holgate S, Bisgaard H, Bjermer L, Haahtela T, Haughney J, Horne R, McIvor A, et al. The Brussels Declaration: the need for change in asthma management. Eur Respir J 2008;32:1433–1442
- Molimard M, Le Gros V, Robinson P, Bourdeix I. Prevalence and associated factors of oropharyngeal side effects in users of ICS in a real-life setting. J Aerosol Med Pulm Drug Deliv 2010;23:91–95
- Bhalla RK, Watson G, Taylor W, Jones AS, Roland NJ. Prospective, randomized cross-over trial to assess the ability of a DPI to reverse the local side effects of pressurized metered-dose inhalers. J Asthma 2008;45:814–819
- Kajiwara A, Saruwatari J, Sakata M, Morita K, Kita A, Oniki K, Yamamura M, et al. Risk Factors for adverse symptoms during dipeptidyl peptidase-IV inhibitor therapy: aquestionnaire-based study carried out by the JPA DEM Project in Kumamoto Prefecture. Drug Saf 2013;36:981--987
- Nave R, Mueller H. From inhaler to lung: clinical implications of the formulations of ciclesonide and other ICS. Int J Gen Med 2013;6:99–107
- Huang J, Shen H, Takahashi M, Fukunaga T, Toga H, Takahashi K, Ohya N. Pharyngeal cross-sectional area and pharyngeal compliance in normal males and females. Respiration 1998;65:458–468
- Bergdahl M. Salivary flow and oral complaints in adult dental patients. Community Dent Oral Epidemiol 2000;28:59–66
- Zitzmann NU, Schilling J, Weiger R, Pastoret MH, Loretan P. Gender-specific dental health issues and treatment considerations. Int J Prosthodont 2007;20:360–368
- Saito J, Sato S, Fukuhara A, Sato Y, Nikaido T, Inokoshi Y, Fukuhara N, et al. Association of asthma education with asthma control evaluated by asthma control test, FEV1, and fractional exhaled nitric oxide. J Asthma 2013;50:97–102
- Peters SP, Prenner BM, Mezzanotte WS, Martin P, O'Brien CD. Long-term safety and asthma control with budesonide/formoterol versus budesonide pressurized metered-dose inhaler in asthma patients. Allergy Asthma Proc 2008;29:499–516
- Yokoyama H, Yamamura Y, Ozeki T, Iga T, Yamada Y. Effects of mouth washing procedures on removal of budesonide inhaled by using Turbuhaler. Yakugaku Zasshi 2007;127:1245–1249